The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 12, 2017

Filed:

Aug. 18, 2014
Applicants:

Benjamin L. Miller, Penfield, NY (US);

Anna DE Benedetto, Rochester, NY (US);

Lisa A. Beck, Rochester, NY (US);

Elizabeth A. Anderson, Rochester, NY (US);

Inventors:

Benjamin L. Miller, Penfield, NY (US);

Anna De Benedetto, Rochester, NY (US);

Lisa A. Beck, Rochester, NY (US);

Elizabeth A. Anderson, Rochester, NY (US);

Assignee:

University of Rochester, Rochester, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 38/44 (2006.01); A61K 39/145 (2006.01); C12N 7/00 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/17 (2013.01); A61K 9/0014 (2013.01); A61K 9/0043 (2013.01); A61K 38/44 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/39 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); A61K 2039/54 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55516 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/16071 (2013.01); C12N 2760/16134 (2013.01); C12Y 113/12007 (2013.01);
Abstract

According to aspects illustrated herein, there is provided an agent that transiently disrupts claudin-1 within tight junctions. The agent includes a peptide having at least 40% polar, uncharged amino acid residues and a self-assembled β-sheet secondary structure. According to aspects illustrated herein, there is also provided a transepithelial drug and vaccine formulations, as well as isolated peptides, pharmaceutical compositions, and transdermal delivery devices. Also described herein are methods of disrupting epithelial barrier and methods of administering the transepithelial formulations described herein.


Find Patent Forward Citations

Loading…